You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
百奧泰(688177.SH):BAT8001 III期臨牀試驗未達預期
格隆匯 02-08 16:23

格隆匯2月8日丨百奧泰(688177.SH)公佈,公司的BAT8001 III期臨牀終點事件數達到方案規定可以進行統計分析的要求。近日,根據公司的初步統計分析主要療效指標無進展生存期(PFS)相比對照組(拉帕替尼聯合卡培他濱)未達到預設的優效目標。基於目前的初步分析結果,公司計劃未來與國家藥品監督管理局(NMPA)做進一步溝通。

BAT8001是公司自主研發的抗體偶聯藥物,由抗HER2單克隆抗體通過穩定的硫醚鍵與毒素-連接子Batansine(一種美登素衍生物)進行共價連接而成。BAT8001結合到HER2受體的第Ⅳ小區後,開始以受體介導進行細胞內化,之後的溶酶體降解過程導致在細胞內釋放含有半胱氨酸-Batansine的細胞毒性代謝物。半胱氨酸-Batansine結合到微管蛋白的過程會破壞細胞內的微管網絡,引起細胞週期阻滯與細胞凋亡。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account